Influenza is a major health problem that can result in hospitalization or even death among high-risk groups such as babies and small children, elderly or immunocompromised persons. According to the World Health Organization (WHO): “Influenza occurs globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children”.1
The recent outbreaks of influenza have created a higher demand for oseltamivir, particularly in the oral liquid dose form.2 SyrSpend® SF is an oral liquid suspending vehicle that does not contain alcohol, sorbitol and in case of the dry version no preservatives. This makes SyrSpend® SF especially suitable for children and other vulnerable patient groups, patients with dysphagia or those in need of a tailored dose.
Oseltamivir phosphate compounded in SyrSpend® SF PH4 has a proven beyond use date of at least 30 days.3 The compounding instructions for oseltamivir phosphate in SyrSpend® SF PH4 can be found in our free online formulations database Compounding Matters.
1. World Health Organization (WHO). Influenza (Seasonal) fact sheet N° 211, March 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
2. The Global Influenza Programme by the World Health Organization (WHO). Influenza update 258, March 2016. Available from: http://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/
3. Voudrie li MA, Allen DB. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup and SyrSpend SF (For Reconstitution). International Journal of Pharmaceutical Compounding, February 2014.